Hazard Ratio (95% CI) | Chi-squared | P Value | Points | |
---|---|---|---|---|
Predictive model for 3-month VTE and points assigned to each independent risk factor | ||||
VTE risk factor | ||||
Previous VTE | 5.0 (3.3-7.8) | 53 | <.001 | 3 |
Known thrombophilia | 5.2 (1.3-21.5) | 5.2 | .02 | 3 |
Current cancer | 2.0 (1.3-3.1) | 11 | .001 | 1 |
Age >60 years | 1.8 (1.2-2.7) | 8.5 | .004 | 1 |
Associative model for 3-month VTE and points assigned each patient characteristic | ||||
Patient characteristic | ||||
Previous VTE | 4.7 (3.0-7.2) | 48 | <.001 | 3 |
Known thrombophilia | 3.5 (1.1-11) | 5.2 | .04 | 2 |
Current lower limb paralysis | 3.0 (1.6-5.7) | 11 | .001 | 2 |
Current cancer | 2.8 (1.9-4.2) | 27 | <.001 | 2 |
Immobilized ≥7 days | 1.9 (1.3-2.7) | 11 | .001 | 1 |
ICU/CCU stay | 1.8 (1.1-2.9) | 6.1 | .01 | 1 |
Age >60 years | 1.7 (1.1-2.6) | 6.3 | .01 | 1 |
References
- Derivation and validation of a simple model to identify venous thromboembolism risk in medical patients.Am J Med. 2011; 124: 947-954
- Upper vs lower extremity deep vein thrombosis: outcome definitions of venous thromboembolism for clinical predictor rules or risk factor analyses in hospitalized patients.J Thromb Haemost. 2009; 7: 1041-1042
- Predictive and associative models to identify hospitalized medical patients at risk for VTE.Chest. 2011; 140: 706-714
Article info
Footnotes
Funding: None.
Conflict of Interest: Dr Spyropoulos has no relevant conflicts of interest to declare. Dr Anderson has received research support from sanofi-aventis, The Medicines Company, Procter & Gamble, and Scios; has been a consultant for sanofi-aventis, GlaxoSmithKline, and Millennium and Sage; and has served on advisory boards for sanofi-aventis and The Medicines Company.
Authorship: All authors had access to the data and a role in the reviewing and writing of this manuscript.
Identification
Copyright
ScienceDirect
Access this article on ScienceDirectLinked Article
- Derivation and Validation of a Simple Model to Identify Venous Thromboembolism Risk in Medical PatientsThe American Journal of MedicineVol. 124Issue 10
- PreviewFewer than half of eligible hospitalized medical patients receive appropriate venous thromboembolism (VTE) prophylaxis. One reason for this low rate is the complexity of existing risk assessment models. A simple set of easily identifiable risk factors that are highly predictive of VTE among hospitalized medical patients may enhance appropriate thromboprophylaxis.
- Full-Text
- Preview
- The ReplyThe American Journal of MedicineVol. 125Issue 11
- PreviewWe congratulate Spyropoulos et al on their recent publication of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) registry findings1 and are grateful for their thoughtful comments. We agree that our research using International Classification of Diseases, Ninth Revision (ICD-9) codes for outcomes is inherently limited by the accuracy of ICD-9 coding and the retrospective nature of data extraction and analysis. In our case, coding limitations may have led to a portion of patients that experienced upper-extremity deep venous thrombosis, superficial thrombophlebitis, or chronic deep venous thrombosis being included among the group classified as having deep venous thrombosis, increasing our observed rate of venous thromboembolism.
- Full-Text
- Preview